Location: USC Michelson Hall
Translation is the process of converting results in basic research into results that directly benefit humans. But what can the path from lab to market look like? Join us on April 6th at the USC Michelson Hall for a live dialogue with experts who will share their translational research journey.
Speakers:
Auriane Gamelin, MBA Entrepreneurship and Finances, Co-Founder and COO of OncoXome, has held operational roles at Fortune 500 companies for over a decade. With this operational experience, Ms. Gamelin decided to fully commit to advancing cancer research and started OncoXome with her father, Erick. Auriane earned certifications in drug development processes from UC-Berkeley and completed a training program in clinical investigations at the FDA headquarters.
Dr. Erick Gamelin, MD, PhD, Co-Founder, CEO & CSO of OncoXome, Dr. Gamelni is a senior executive in the pharmaceutical industry, a former professor of oncology, leader of a research lab, and a globally renowned expert in oncogenomics and molecular pharmacology. He has dedicated thirty years to oncology, conducting basic, translational, and clinical research both in academia (part of his post-doc at the NIH, Therapeutic Branch) and in the pharmaceutical industry. While in academia, Dr. Gamelin participated in bringing several drugs to market such as paclitaxel, oxaliplatin and nab-paclitaxel. He is a co- inventor on eight international patents and has published more than 140 scientific articles in international peer-reviewed journals.
Valery Fokin, Ph.D. Professor of Chemistry, USC, Valery V. Fokin received his Ph.D. degree in 1998 from the University of Southern California, where he worked under the direction of Professor Nicos A. Petasis. He then joined the group of Nobel Prize Winner Professor K. Barry Sharpless at The Scripps Research Institute in La Jolla, California as a postdoctoral fellow, where he studied catalytic oxidations of olefins. In 2001, he was appointed assistant, and in 2006 associate professor in the Chemistry Department at Scripps. His research is centered on understanding of the chemical reactivity and its applications in chemistry, biology, and materials science.
Dr Bodhour Salhia Ph.D., USC, Dr. Salhia is a translational genomics scientist with extensive knowledge and expertise in mechanisms that underlie tumorigenesis and tumor biology. She merges cutting edge genomics/epigenomics analyses with cell biological and functional studies towards the investigation of clinically relevant problems in human cancer. She has led and continues to lead numerous DNA methylation studies using a plethora of both array and sequencing based technologies to measure whole genome and targeted CpG methylation changes in a variety of cancer types.
Moderator:
Vasiliki Anest,Ph.D USC, Dr. Anest serves as the Chief Innovation Officer for USC Norris. She leads the development of innovation strategies and builds high‐value industry collaborations and strategic partnerships throughout USC and externally. Dr. Anest also serves as Senior Director of Business Development and Industry Relations at the MESH Academy and Business Director of the Rosalie and Harold Rae Brown Center for Cancer Drug Development at USC Norris. She has forged collaborative relationships and formulated unique partnering strategies with university, government, and industry partners.